TY - JOUR
T1 - The Liverpool Heart And bRain Project (L-HARP)
T2 - Protocol for an Observational Cohort Study of Cardiovascular Risk and Outcomes Following Stroke
AU - Harrison, Stephanie L.
AU - Lane, Deirdre A.
AU - Buckley, Benjamin J.R.
AU - Chatterjee, Kausik
AU - Alobaida, Muath
AU - Shipley, Emily
AU - Lip, Gregory Y.H.
N1 - Funding Information:
The study has received the approval from Health Research Authority Research Ethics Committee (21/WA/0209), and the University of Liverpool is the sponsor for the project (UoL001512). The study is supported with part-funding from Bristol-Myers Squibb, as well as a National Institute for Health Research (NIHR) Senior Investigator grant to Professor Lip.
Funding Information:
SLH reports grants from Bristol Myers Squibb (BMS) during the conduct of the study. DAL reports grants from BMS and personal fees from Boehringer Ingelheim and BMS/Pfizer outside the submitted work; received investigator-initiated educational grants from BMS, has been a speaker for Bayer, Boehringer Ingelheim, and BMS/Pfizer, and has consulted for BMS and Boehringer Ingelheim. BJRB: received funding from BMS/Pfizer. KC, MA and ES report no conflicts of interest. GYHL reports being a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo and speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. The authors report no other potential conflicts of interest for this work.
Publisher Copyright:
© 2022 Harrison et al.
PY - 2022
Y1 - 2022
N2 - Further research is needed to refine risk prediction models for adverse cardiovascular outcomes following stroke in contemporary clinical practice, such as incident atrial fibrillation (AF), recurrent stroke, and cognitive impairment and dementia. The aims of this study are to prospectively investigate cardiovascular outcomes and risk factors for incident cardiovascular disease in a post-stroke cohort, and to externally validate, refine and expand current risk prediction models for cardiovascular and cardiovascular-related outcomes. The study sample size was based on the development of post-stroke risk prediction models for AF and was calculated as 1222 participants. The study design is a multicentre, prospective, observational cohort study. Participants will be adult patients admitted for ischaemic stroke confirmed by stroke physician or transient ischaemic attack (TIA) confirmed by MRI. Routinely collected data will be used in addition to the completion of simple validated questionnaires by the participants. Follow-up will be undertaken 12-months from the date of admission to hospital, in addition to linkage to routinely collected follow-up hospitalisation and mortality data. The primary outcomes are cardiovascular outcomes (including incident AF, stroke, TIA and myocardial infarction) at 12-month follow-up, all-cause mortality and mortality from cardiovascular causes, and incident cognitive impairment and dementia. Secondary outcomes include changes in function, depression, anxiety, fatigue and quality of life. The study has received approval from the Health Research Authority Research Ethics Committee (21/WA/0209), and is registered on https://www.clinicaltrials.gov/ (Identifier NCT05132465). Recruitment for the study began in October 2021 with completion of recruitment at all participating centres anticipated by October 2022.
AB - Further research is needed to refine risk prediction models for adverse cardiovascular outcomes following stroke in contemporary clinical practice, such as incident atrial fibrillation (AF), recurrent stroke, and cognitive impairment and dementia. The aims of this study are to prospectively investigate cardiovascular outcomes and risk factors for incident cardiovascular disease in a post-stroke cohort, and to externally validate, refine and expand current risk prediction models for cardiovascular and cardiovascular-related outcomes. The study sample size was based on the development of post-stroke risk prediction models for AF and was calculated as 1222 participants. The study design is a multicentre, prospective, observational cohort study. Participants will be adult patients admitted for ischaemic stroke confirmed by stroke physician or transient ischaemic attack (TIA) confirmed by MRI. Routinely collected data will be used in addition to the completion of simple validated questionnaires by the participants. Follow-up will be undertaken 12-months from the date of admission to hospital, in addition to linkage to routinely collected follow-up hospitalisation and mortality data. The primary outcomes are cardiovascular outcomes (including incident AF, stroke, TIA and myocardial infarction) at 12-month follow-up, all-cause mortality and mortality from cardiovascular causes, and incident cognitive impairment and dementia. Secondary outcomes include changes in function, depression, anxiety, fatigue and quality of life. The study has received approval from the Health Research Authority Research Ethics Committee (21/WA/0209), and is registered on https://www.clinicaltrials.gov/ (Identifier NCT05132465). Recruitment for the study began in October 2021 with completion of recruitment at all participating centres anticipated by October 2022.
KW - cohort study
KW - epidemiology
KW - risk prediction
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85129355095&partnerID=8YFLogxK
U2 - 10.2147/VHRM.S357829
DO - 10.2147/VHRM.S357829
M3 - Article
C2 - 35502192
AN - SCOPUS:85129355095
SN - 1176-6344
VL - 18
SP - 313
EP - 318
JO - Vascular Health and Risk Management
JF - Vascular Health and Risk Management
ER -